% | $
Quotes you view appear here for quick access.

Venaxis, Inc. Message Board

  • galaberge galaberge Jul 26, 2013 10:36 AM Flag

    Everyone should know how precise is the novel appendicitis test (APPY1) for young patients (age 2-21).

    The proprietary blood test and reader helps doctors rule out appendicitis in kids without them having to undergo an expensive and cancer-risked CT scan. The breakthrough diagnostic test has already been granted marketing approval (CE Mark) in Europe where a launch in multiple countries (U.K., Germany, Italy, France, Turkey, Netherlands) is currently underway. In the U.S., APPY is currently conducting a 2,000 patient, pivotal Phase 3 study with results expected in Q4 2013.

    Everyone should know how precise is the APPY1 test

    NPV = Probability that a patient with a negative test result will not have the disease is 97% !!!!!

    Sensitivity = Probability that a patient with the disease will have a positive test result is 97% !!!!

    The market is so HUGE that we have a 685% Increase in Institutional ownership of APPY in Q1-Q2 2013 from 304,584 shares to 2,392,844 shares !!!!! at a median price of $2.40

    So it's time to get your tickets for the train en route to at least $7.00

    Enjoy the ride.

    Long and strong APPY

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.5474+0.0081(+1.50%)3:56 PMEDT